Core Viewpoint - The announcement details a change in the equity structure of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. due to the passive reduction of shares held by its controlling shareholder, Heilongjiang Chuangda Group Co., Ltd., following the conversion of exchangeable bonds [2][3]. Group 1: Equity Change Overview - After the equity change, Heilongjiang Chuangda Group holds 516,973,085 shares, representing 54.94% of the total share capital of Zhenbaodao [2][3]. - The equity change is a result of the conversion of exchangeable bonds issued by Chuangda Group, leading to a decrease in its shareholding from 55.86% to 54.94% [3][4]. Group 2: Details of the Equity Change - From February 5 to February 9, 2026, a total of 8,709,675 shares were converted, accounting for approximately 0.93% of the total share capital [4][11]. - The equity change does not trigger a mandatory tender offer and will not alter the controlling shareholder or actual controller of the company [2][5]. Group 3: Future Plans and Compliance - Chuangda Group's exchangeable bonds are currently in the conversion period, and the company will continue to monitor the conversion activities [5][8]. - The company has committed to fulfilling its information disclosure obligations in accordance with relevant laws and regulations [5][8].

登录新浪财经APP 搜索【信披】查看更多考评等级 重要内容提示： ■ 一、信息披露义务人及其一致行动人的基本信息 1.身份类别 ■ 证券代码：603567证券简称：珍宝岛公告编号：临2026-009 黑龙江珍宝岛药业股份有限公司 关于控股股东权益变动触及1%刻度的提示性公告 黑龙江创达集团有限公司保证向本公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 2.信息披露义务人信息 ■ 3.一致行动人信息 上述信息披露义务人无一致行动人。 二、权益变动触及1%刻度的基本情况 黑龙江珍宝岛药业股份有限公司(以下简称"公司")于2026年2月5日收到公司控股股东黑龙江创达集团有 限公司（以下简称"创达集团"）的通知,获悉创达集团发行的2023年面向专业投资者非公开发行可交换 公司债券（第一期）和2023年面向专业投资者非公开发行可交换公司债券（第二期）的债券持有人于 2026年1月13日-2026年2月4日发生换股10,511,854股，导致创达集团持股比例被动下降，持有公司股份 比例从56.98%减少至55.86%，权益变动触及 ...